TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine in the Perioperative Treatment of Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients are 18 years or older and have histologically confirmed adenocarcinoma of the rectum (defined as the distal border of the tumour less than 16 cm from the anal verge measured by rigid rectoscopy) with no evidence of distant metastases (identified by abdominal ultrasound or CT scan and chest radiography).~* Patients in the adjuvant cohort have undergone R0-resection by total mesorectal excision (TME) of a pT3-4 N any or T any N positive non-metastatic rectal cancer.~* Patients treated in the neoadjuvant cohort need to have a clinical T3-4 N any or T any N positive tumour staged by endoscopic ultrasound, provided the lower border of the tumour is located 0 - 16 cm from the anal verge measured by rigid rectoscopy and the primary tumour is deemed resectable by TME surgery on the basis of clinical assessment. Other eligibility criteria comprise: WHO status of zero or one; adequate liver, renal, and bone marrow function defined as follows: leucocyte count \> 3,500/µl, thrombocyte count \> 100,000/µl, hemoglobin \> 10.0 g/dl; serum bilirubin \< 2.0 mg/dl, serum creatinine \< 2.0 mg/dl.~Exclusion criteria:~* Prior treatment for rectal cancer, prior chemo- or immunotherapy, prior pelvic radiotherapy, or a history of other malignant diseases within the past five years with the exception of successfully treated basal carcinoma of the skin or carcinoma in situ of the uterine cervix.~* Participation in another trial, pregnancy, breast-feeding, unwillingness to use effective contraception, or a medical condition or concomitant illness which could potentially interfere with compliance to the protocol are regarded as exclusion criteria, as well.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5-Fluorouracil (5-FU) (Type: ACTIVE_COMPARATOR): Drug - 5FU based chemoradiotherapy and chemotherapy
- Capecitabine (Type: EXPERIMENTAL): Drug - Capecitabine-based radiochemotherapy and chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 of age~* Must meet the criteria for major depressive disorder~* You must be able to visit the doctor's office about once a week for 2 to 3 months. After that, you will need to visit the doctor's office once a month for about 6 months~* You must be able to take the study drug as prescribed (6 capsules per day taken once-daily)~Exclusion Criteria:~* You are a woman and are pregnant or breastfeeding.~* You have a current or previous major psychiatric disorder other than depression, such as bipolar disorder, schizophrenia, or other psychotic disorder.~* You have a history of alcohol or drug dependence within the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed documented deleterious or suspected deleterious BRCA mutation. (The presence of a loss-of-function germline mutation in the BRCA1 and/or BRCA2 gene must be confirmed prior to consent according to local practice).~* Confirmed malignant solid tumours for which no standard treatment exists~* At least one lesion (measurable and/or non measurable) at baseline that can be accurately assessed by CT/MRI and is suitable for repeated assessment at follow up visits~Exclusion Criteria:~* Any previous treatment with a PARP inhibitor, including olaparib~* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication~* Patients receiving any systematic chemotherapy, radiotherapy (except for palliative reasons) within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator. Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postmenopausal Women Estrogen and Progesterone Infusion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~postmenopausal women young (age 45-55) or old (age 70-80) History of natural menopause defined by the absence of menses for at least 12 months (or history of surgical menopause defined as bilateral oophorectomy) Normal TSH, PRL and CBC, and Factor V activity Normal BUN and Creatinine (\< 2 times the upper limit of normal) BMI between 18 to 30 kg/m2 An increased FSH measured at the screening visit will be consistent with menopause. If the initial determination is low, a repeat sample may be drawn.~Exclusion criteria:~Hormonal medication or herbal supplements and/or over the counter menopause therapy in the 2 months prior to study Any absolute contraindications to the use of physiologic replacement doses of estrogen and/or progesterone History of coronary artery disease Medications thought to act centrally on the GnRH pulse generator History of breast cancer or blood clots Smoking more than 10 cigarettes/day Prior history of allergic reaction to any dyes used with x-rays or scans and/ or any other contraindications to PET scans No metal implants, pacemakers, aneurysm clips, implanted hearing aids and/or any other contraindications to MRI scan

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Young postmenopausal women (Type: ACTIVE_COMPARATOR): Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
- Older postmenopausal women (Type: ACTIVE_COMPARATOR): Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allogenic Cord Blood Transfusion in Patients With Autism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis: autistic type disorder (ASD).~* Systemic speech underdevelopment~* The presence of attention deficit hyperactivity disorder as a comorbid state~* Cognitive impairment~Exclusion Criteria:~* organic pathology of the brain according to CT, MRI~* the presence of the following diseases in history: heart failure in the stage of decompensation, stroke in history less than 1 year ago, blood diseases;~* decompensation of chronic and endocrinological diseases;~* acute respiratory viral and bacterial infections, period less than 1 month after the acute phase.~* HIV infection, hepatitis B and C.~* oncological diseases, chemotherapy in the anamnesis;~* tuberculosis.~* Severe form of intellectual disability.~* Cerebral palsy.~* epilepsy.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- ASD CB-MNC injection. (Type: EXPERIMENTAL): ASD CB-MNC injection from different donors and standard therapy.
- Standard therapy. (Type: OTHER): Patients with standard therapy as control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult female or post-menarche adolescent girl ≥12 years of age in general good health~* Have a diagnosis of trichomoniasis at the screening visit as determined by one of the following:~  * positive T. vaginalis NAAT test within 30 days of screening for which treatment has not been initiated.~ * positive OSOM® rapid test.~ * positive wet mount assessment.~* Agree to abstain from vaginal intercourse until the final study visit~* Agree not to have any vaginal penetration or use of any vaginal products for the duration of the study~Exclusion Criteria:~* Are pregnant, lactating, or planning to become pregnant during the study.~* Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including symptomatic vulvovaginal candidiasis, chlamydia, gonorrhea, or an active genital herpes outbreak~* Are suspected clinically of having an acute urinary tract infection.~* Have active genital lesions, including primary syphilitic chancres and herpes simplex virus lesions, or other vaginal or vulvar conditions which could confound the interpretation of the clinical response, as determined by the Investigator (patients with genital warts may be enrolled).~* Have received systemic antibacterial therapy or topical antimicrobial/antifungal/ immunomodulatory therapies in the genital area (vagina, vulva and surrounding soft tissue), within 14 days prior to the Baseline Visit (Day 1).

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solosec (containing 2 grams of secnidazole) (Type: EXPERIMENTAL): Orally administered as a single dose with applesauce.
- Placebo (Type: PLACEBO_COMPARATOR): Orally administered as a single dose with applesauce.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of congestive heart failure in NYHA class II~* Left ventricular ejection fraction \<= 45% measured within 6 months from enrolment~* Stable standard heart failure therapy (if patients are on beta blocker drugs, treatment must have been started at least three months before enrolment)~* Informed consent (obtained prior of any study procedures)~Exclusion Criteria:~* Age \<18 and \>80~* Serum creatinine level \> 2.5 mg per deciliter~* Serum potassium level \> 5.0 mmol per liter~* Valvular heart disease amenable to surgical treatment~* Congenital heart disease~* Unstable angina and/or acute myocardial infarction and/or coronary revascularization procedure within three months before enrolment~* Intravenous therapy with inotropic drugs within three months before enrolment~* History of resuscitated ventricular fibrillation or tachycardia, unless these occurred within 24 hours of an acute myocardial infarction or the subject has an implanted an automatic cardioverter defibrillator~* Chronic active hepatitis or cirrhosis~* Malignant neoplasm or any life threatening non cardiac disease~* History of hypersensitivity to study drug~* Pregnancy or lactating or childbearing age women who are not protected by an accepted method of contraception~* History of drug or alcohol abuse~* Legal incapacity and/or other circumstances rending the patient unable to understand the nature, scope and possible consequences of the study.~* Evidence of uncooperative attitude~* Any condition other than heart failure that does not permit an optimal participation to the trial~* Participation to other RCTs during the last 3 months~* Treatment with: Lithium salts, Potassium sparing diuretics, oral positive inotropic drugs or any investigational drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject with a confirmed diagnosis consistent with idiopathic generalized epilepsy experiencing primary generalized tonic-clonic seizures (IIE) that are classifiable according to the ILAE Classification of Epileptic Seizures.~* Presence of at least 3 PGTC seizures during the 8-week combined Baseline period.~* Absence of brain lesion documented on a CT scan or MRI.~* An EEG performed within 1 year of Visit 1 with features consistent with PGTC seizures or generalized idiopathic epilepsy.~* Male/female subject, \>=4 or \<=65 years of age at Visit 1.~* Subject on a stable dose of one or two AEDs during baseline.~Exclusion Criteria:~* Previous exposure to levetiracetam.~* History of partial seizures.~* History of convulsive or non-convulsive status epilepticus while taking concomitant AEDs within three months prior to Visit 1.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a recipient of a de novo kidney from a living or deceased donor~Exclusion Criteria:~* Subject has induction therapy, other than study-assigned basiliximab, planned as part of initial immunosuppressive regimen~* Subject has previously received or is receiving an organ transplant other than a kidney~* Subject will receive a solitary kidney from a deceased donor \< 5 years of age~* Subject will receive a kidney with an anticipated cold ischemia time (CIT) of \> 30 hours~* Subject will receive a kidney that meets both Extended Criteria Donor (ECD) and Donation after Cardiac Death (DCD) criteria. Note: a kidney that meets either ECD or DCD criteria is eligible for inclusion~* Subject will receive an ABO incompatible donor kidney~* Subject has a current calculated panel reactive antibody (cPRA) level \>50%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Basiliximab induction + Tacrolimus + MMF + Corticosteroids
- CNI avoidance (Type: EXPERIMENTAL): Basiliximab induction + ASKP1240 + MMF + Corticosteroids
- CNI minimization-MMF avoidance (Type: EXPERIMENTAL): Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-myeloid malignancy~* At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless of schedule~* Eastern Cooperative Oncology Group performance status of 0-2~* Hemoglobin concentration of less than 11 g/dL within 24 hours before randomization~* Of legal age at the time written informed consent is obtained~Exclusion Criteria:~* Known history of seizure disorder~* Known primary hematologic disorder, which could cause anemia, other than a non-myeloid malignancy~* Unstable or uncontrolled disease/condition, related to or affecting cardiac function~* Clinically significant inflammatory disease~* Inadequate renal and/or liver function~* Known positive HIV test~* Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO~* Received more than 2 red blood cell (RBC) transfusions within 4 weeks before randomization or any RBC transfusion within 14 days before randomization, or any planned RBC transfusion between randomization and study day 1~* Received any erythropoietic therapy within 4 weeks before randomization or any planned erythropoietic therapy between randomization and study day 1~* Other investigational procedures~* Subject is currently enrolled in or less than 30 days since receipt of any investigational drug or device that is not approved by the applicable regulatory authority~* Pregnant or breast feeding~* Not using adequate contraceptive precautions~* Known sensitivity to any of the products to be administered during dosing~* Previously randomized in this study~* Concerns for subject's compliance with protocol procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa 500 mcg - Group A (Type: EXPERIMENTAL): None
- Darbepoetin alfa 2.25 mcg/kg - Group B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men above age of majority~* Mild erectile dysfunction (IIEF-EF 22-25) and sexual dissatisfaction (IIEF-OS 7 or less)~Exclusion Criteria:~* Use of more than 4 doses of any PDE5 inhibitor in the past 12 weeks and use of any PDE5 inhibitor in the past 4 weeks~* Subjects currently taking any other commercially available drug or non-drug treatment for ED

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus.~2. Male and female patients on diet and exercise regimen, pre-treated with immediate release metformin for at least 12 weeks, and patients should be on a dose higher or equal to 1500 mg/day of metformin, or maximum tolerated dose, or maximum dose as per local label.~3. HbA1c higher or equal to 8.0% and lower or equal to 10.5% at screening visit.~4. Age 18 years or more at screening.~5. Body Mass Index lower or equal to 45 kg/m2 at screening visit.~6. Signed and dated written informed consent.~Exclusion criteria:~1. Uncontrolled hyperglycemia with glucose level above 270 mg/dl (above 15 mmol/dl) after an overnight fast.~2. Use of any other antidiabetic drug (except metformin background therapy).~3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent.~4. Indication of liver disease.~5. Impaired renal function.~6. Gastrointestinal surgery.~7. Treatment with anti-obesity drugs within 3 months prior to screening, or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.~8. Current treatment with systemic steroids at time of informed consent or uncontrolled endocrine disorder except type 2 diabetes mellitus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: ACTIVE_COMPARATOR): 5 mg once daily
- Empagliflozin + Linagliptin low dose (Type: EXPERIMENTAL): 1 tablet once daily
- Empagliflozin + Linagliptin high dose (Type: EXPERIMENTAL): 1 tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete